Starpharma Holdings (SPL) Stock Overview

A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. More details

SPL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 79.2% below our estimate of its fair value

Earnings are forecast to grow 92.03% per year

Earnings have grown 23% per year over the past 5 years

Risk Analysis

No risks detected for SPL from our risk checks.

SPL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW435,612 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

435,612 investors already sharing narratives

View all narratives

Starpharma Holdings Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Starpharma Holdings
Historical stock prices
Current Share Price	AU$0.82
52 Week High	AU$0.82
52 Week Low	AU$0.12
Beta	0.76
1 Month Change	2.83%
3 Month Change	22.01%
1 Year Change	581.25%
3 Year Change	419.05%
5 Year Change	-40.97%
Change since IPO	25.77%

Recent updates

Shareholder Returns

	SPL	AU Pharmaceuticals	AU Market
7D	12.8%	3.3%	-0.6%
1Y	581.3%	-5.4%	-0.3%

Return vs Industry: SPL exceeded the Australian Pharmaceuticals industry which returned -5.6% over the past year.

Return vs Market: SPL exceeded the Australian Market which returned 0% over the past year.

Price Volatility

Is SPL's price volatile compared to industry and market?
SPL volatility
SPL Average Weekly Movement	5.7%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	9.7%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	4.0%

Stable Share Price: SPL has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: SPL's weekly volatility has decreased from 16% to 6% over the past year.

About the Company

Founded	Employees	CEO	Website
1997	50	Cheryl Maley	starpharma.com

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.

Starpharma Holdings Limited Fundamentals Summary

How do Starpharma Holdings's earnings and revenue compare to its market cap?
SPL fundamental statistics
Market cap	AU$386.25m
Earnings (TTM)	-AU$7.46m
Revenue (TTM)	AU$12.67m

30.5x

P/S Ratio

-51.7x

P/E Ratio

Is SPL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPL income statement (TTM)
Revenue	AU$12.67m
Cost of Revenue	AU$11.89m
Gross Profit	AU$774.00k
Other Expenses	AU$8.24m
Earnings	-AU$7.46m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.016
Gross Margin	6.11%
Net Profit Margin	-58.93%
Debt/Equity Ratio	2.6%

How did SPL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/09 06:01
End of Day Share Price	2026/09/09 00:00
Earnings	2026/06/30
Annual Earnings	2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Starpharma Holdings Limited is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Matthijs Smith	Canaccord Genuity
Derek Jellinek	CGS International
Waradana Malitha De Silva	CLSA

Starpharma Holdings (SPL) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Starpharma Holdings Limited Competitors

Mayne Pharma Group

Vita Life Sciences

Recce Pharmaceuticals

Arovella Therapeutics

Price History & Performance

Recent News & Updates

Full year 2026 earnings released: AU$0.02 loss per share (vs AU$0.024 loss in FY 2025)

Starpharma Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 31.990561 million.

Forecast to breakeven in 2027

Forecast to breakeven in 2027

Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025

Full year 2025 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in FY 2024)

Recent updates

Full year 2026 earnings released: AU$0.02 loss per share (vs AU$0.024 loss in FY 2025)

Starpharma Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 31.990561 million.

Forecast to breakeven in 2027

Forecast to breakeven in 2027

Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025

Full year 2025 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in FY 2024)

Less than half of directors are independent

Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024

Full year 2024 earnings released: AU$0.02 loss per share (vs AU$0.038 loss in FY 2023)

Non-Executive Director recently bought AU$80k worth of stock

First half 2024 earnings released: AU$0.003 loss per share (vs AU$0.02 loss in 1H 2023)

Starpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024

Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023

Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold Viruses

No independent directors

Starpharma Holdings Limited Announces Change of Company Secretary

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.04 loss in FY 2022)

New minor risk - Share price stability

Starpharma Announces Resignation of Jackie Fairley as Chief Executive Officer

New minor risk - Market cap size

First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)

Starpharma Holdings Limited Announces Board Changes

Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023

Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.05 loss in FY 2021)

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Independent Non-Executive Director recently bought AU$71k worth of stock

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.039 loss in FY 2020)

Independent Non-Executive Deputy Chairman Peter Turvey has left the company

New 90-day high: AU$1.79

New 90-day high: AU$1.66

New 90-day low: AU$1.27

Shareholder Returns

Price Volatility

About the Company

Starpharma Holdings Limited Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources